(Q34124650)

English

Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Samuel R Denmeade

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

John T Isaacs

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

70

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1600-1607

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Androgen biosynthetic pathways in the human prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Characterization of PacMetUT1, a recently isolated human prostate cancer cell line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

AR, the cell cycle, and prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Ligand-specific dynamics of the androgen receptor at its response element in living cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Molecular determinants of resistance to antiandrogen therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Hsp90 as a therapeutic target in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

VCaP, a cell-based model system of human prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Complete androgen blockade for prostate cancer: what went wrong?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Androgen-repressed phenotype in human prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Response of men with advanced prostatic carcinoma to exogenous administration of testosterone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Negative controls of cell proliferation: human prostate cancer cells and androgens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

5 July 2018

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

28 October 2018

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

28 October 2018

Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

28 October 2018

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

28 October 2018

Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

28 October 2018

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124628

28 October 2018

Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20607766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20607766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discussion of Dr. Huggins' paper: Control of cancers of man by endocrinological methods

1 reference

https://pubmed.ncbi.nlm.nih.gov/20607766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of human mammary and prostatic cancers by adrenalectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20607766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostatic cancer; further investigation of hormonal relationships

1 reference

https://pubmed.ncbi.nlm.nih.gov/20607766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/20607766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/20607766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent androgen suppression for prostate cancer: rationale and clinical experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/20607766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/PROS.21196

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34124650&oldid=1856115805"